Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Arena Pharmaceuticals, Inc.    

ARENA PHARMACEUTICALS, INC.
Mes dernières consult.
Most popular
Report
SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 News SummaryMost relevantAll newsSector newsTweets
Most relevant news about ARENA PHARMACEUTICALS, INC
01/08 ARENA PHARMACEUTICALS, INC. (NASDAQ : ARNA) Files An 8-K Regulation FD Disclosur..
01/08 JOHNSON & JOHNSON : J&J Innovation unveils 15 new deals
01/08 ARENA PHARMACEUTICALS, INC. (NASDAQ : ARNA) Files An 8-K Results of Operations a..
2017 ARENA PHARMACEUTICALS : to Present at the 36th Annual J.P. Morgan Healthcare Con..
2017 ARENA PHARMACEUTICALS : to Present at the 36th Annual J.P. Morgan Healthcare Con..
2017 ARENA PHARMACEUTICALS : and Everest Medicines Enter into Development and Commerc..
2017 ARENA PHARMACEUTICALS, INC. (NASDAQ : ARNA) Files An 8-K Other Events
2017 ARENA PHARMACEUTICALS : and Everest Medicines Enter into Development and Commerc..
2017 FDA Nod For BMY's Sprycel, ARNA To Report Data In Q1, MYL Delists From TASE
2017 ARENA PHARMACEUTICALS : Completes Full Enrollment in Etrasimod Phase 2 Clinical ..
2017 ARENA PHARMACEUTICALS : reports 3Q loss
2017 ARENA PHARMACEUTICALS : Provides Corporate Update and Reports Third Quarter 2017..
2017 ARENA PHARMACEUTICALS : to Present at the Credit Suisse Healthcare Conference on..
2017 ARENA PHARMACEUTICALS : to Present at the Credit Suisse Healthcare Conference on..
2017 ARENA PHARMACEUTICALS : to Release Third Quarter 2017 Financial Results and Prov..
More most relevant news
All news about ARENA PHARMACEUTICALS, INC
01/08 ARENA PHARMACEUTICALS, INC. (NASDAQ : ARNA) Files An 8-K Regulation FD Disclosur..
01/08 ARENA PHARMACEUTICALS INC : Regulation FD Disclosure (form 8-K)
01/08 JOHNSON & JOHNSON : J&J Innovation unveils 15 new deals
01/08 ARENA PHARMACEUTICALS, INC. (NASDAQ : ARNA) Files An 8-K Results of Operations a..
01/05 ARENA PHARMACEUTICALS INC : Results of Operations and Financial Condition, Regul..
2017 ARENA PHARMACEUTICALS : to Present at the 36th Annual J.P. Morgan Healthcare Con..
2017 ARENA PHARMACEUTICALS : to Present at the 36th Annual J.P. Morgan Healthcare Con..
2017 ARENA PHARMACEUTICALS : and Everest Medicines Enter into Development and Commerc..
2017 ARENA PHARMACEUTICALS, INC. (NASDAQ : ARNA) Files An 8-K Other Events
2017 ARENA PHARMACEUTICALS INC : Other Events (form 8-K)
More news
Sector news : Biotechnology & Medical Research - NEC
01/17 CELGENE : Conducts Deal Talks With Juno -- WSJ
01/16 CELGENE : in Talks to Buy Juno Therapeutics -- Update
01/16 CELGENE : in Talks to Buy Juno Therapeutics
01/12 Drugmakers see a pricing blueprint in an $850,000 gene therapy
01/12 SPARK'S PRICE FOR LUXTURNA BLINDNESS : Icer
01/08 $11 billion biotech binge fuels forecasts of 2018 M&A surge
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
2017 Arena Pharmaceuticals (ARNA) Presents At JMP Securities Life Sciences Confere..
2017 Arena Pharmaceuticals' (ARNA) CEO Amit Munshi Presents at JMP Securities Life..
2017 Arena continues up move, shares ahead 25% in three days
2017 DRYSHIPS : Rank #1 As Worst Stock In Nasdaq
2017 Stocks to watch next week
2017 PREMARKET LOSERS AS OF 9 : 05 am
Financials ($)
Sales 2017 26,9 M
EBIT 2017 -93,2 M
Net income 2017 -102 M
Finance 2017 246 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 40,4x
EV / Sales 2018 51,1x
Capitalization 1 330 M
Chart ARENA PHARMACEUTICALS, INC
Duration : Period :
Arena Pharmaceuticals, Inc Technical Analysis Chart | US0400471027 | 4-Traders
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 43,0 $
Spread / Average Target 27%
EPS Revisions
Managers
NameTitle
Amit D. Munshi President, Chief Executive Officer & Director
Tina Susan Nova Chairman
Kevin R. Lind Chief Financial Officer & Executive Vice President
John Adams Head-Scientific Affairs
Preston S. Klassen Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ARENA PHARMACEUTICALS, INC.14.01%1 330
CELLTRION, INC.--.--%40 725
IQVIA HOLDINGS INC2.19%20 784
LONZA GROUP1.56%20 682
INCYTE CORPORATION-0.68%19 342
ALNYLAM PHARMACEUTICALS, INC.1.59%12 256